Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) has signed an exclusive multi-year agreement with Geistlich Biomaterials Italia, which will distribute the company’s OrthoPure XT ligament product in Italy.
The company said there was the potential to expand the tie-up to other geographies. No financial details were given.
Investors were told Geistlich said it will help advance the clinical science supporting OrthoPure, with the work conducted by leading Italian clinicians.
Tissue Regenix chief executive Daniel Lee said: "Geistlich is a leader in regenerative products, so our commitments are aligned in delivering innovative products to advance patient care.
“We are excited to work with them to build the clinical experience with OrthoPure XT and introduce this transformative product to the Italian medical community."